Compare DNUT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | GOSS |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.3M | 615.7M |
| IPO Year | 2021 | 2019 |
| Metric | DNUT | GOSS |
|---|---|---|
| Price | $3.13 | $2.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $6.22 | ★ $8.83 |
| AVG Volume (30 Days) | 2.3M | ★ 5.1M |
| Earning Date | 02-24-2026 | 03-12-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,534,272,000.00 | $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.19 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $0.76 |
| 52 Week High | $9.43 | $3.87 |
| Indicator | DNUT | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 42.33 |
| Support Level | $3.03 | $2.32 |
| Resistance Level | $3.31 | $2.76 |
| Average True Range (ATR) | 0.15 | 0.23 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.61 | 22.48 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.